On Friday, the NOVO Nordisk obesity medication was eliminated on Friday by American regulators to treat an increasingly common liver disease, adding to the list of the conditions for which the therapy with superproduction is now approved.
Food and Drug Administration has granted accelerated approval to Wegovy for patients with steatohepatitis associated with metabolic dysfunction, or puree, with moderate to advanced liver scars. The decision was based on the results of phase 3 showing that the drug has helped improve liver scars or fibrosis and resolve symptoms.
Many people with obesity develop a fatty liver disease, which can then progress towards a serious form which is a puree. Puree causes fibrosis, which can then progress towards even more serious scars called cirrhosis, which then leads to liver cancer or the need for a liver transplant.
This article is exclusive to stat + subscribers
Unlock this article – plus daily coverage and analysis of the pharmaceutical industry – as a STAT +subscription.
Do you already have an account? Connect
Show all plans
